Marino Garcia, Dianthus CEO
5AM, Avidity, Fidelity lead $100M infusion into next-gen, targeted complement approach
When the FDA first approved Alexion’s Soliris — then eculizumab — in 2007, experts celebrated how the first-of-its-kind drug transformed the way physicians could treat a rare …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.